Exciting Earnings Call Announcement from STAAR Surgical
STAAR Surgical Company (NASDAQ: STAA), a global frontrunner in the provision of phakic IOLs featuring the innovative EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, has declared an important date in its calendar. The company is gearing up to unveil its financial results for the fourth quarter and the fiscal year ending December 27 in 2024. This much-anticipated announcement will be made on February 19, after the market closes.
Promising Growth Trajectory
In a recent statement, Tom Frinzi, Chair of the Board and CEO, highlighted the accomplishments during the last fiscal year. He noted impressive double-digit year-over-year growth in ICL sales globally, with a slight exception in China. Despite the pervasive economic challenges and fluctuating consumer confidence levels in regions like China, STAAR's EVO ICL technology has proven to be robust.
Market Trends and Opportunities
Frinzi pointed out the significance of the annual Chinese New Year in understanding market dynamics and consumer behavior. As a period that typically influences spending habits, insights gained from this time will be instrumental in shaping the company's approach moving into fiscal 2025.
Details of the Upcoming Webcast
Investors and interested parties are encouraged to participate in the live earnings webcast scheduled for February 19, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. During this session, key financial and operational achievements will be discussed in depth.
Accessing the Live Webcast
The live broadcast will be available online, providing a platform where STAAR will share insights into their fiscal performance and operational advancements. Attendees will have the option to pre-register for this event through the dedicated link on the company’s website.
For those unable to attend, a replay of the webcast will be available approximately three hours post-event and will remain accessible for at least 90 days.
About STAAR Surgical Company
With over four decades dedicated solely to ophthalmic surgery, STAAR has established itself as a leader in the design, manufacturing, and marketing of implantable lenses for visual correction. The company's revolutionary ICL technology aims to provide patients with greater visual freedom, reducing the reliance on traditional eyewear.
The Implantable Collamer® Lens (ICL), particularly the EVO ICL™ line, has seen immense success, with over three million units sold in more than 75 countries. The convenience of these foldable lenses allows for small-incision surgery, making them a favored choice among patients and surgeons alike.
Looking Ahead
The company operates its manufacturing and packaging facilities across various locations in California and Switzerland, ensuring quality and accessibility of their products worldwide. As STAAR Surgical continues to innovate and expand its product line, stakeholders look forward to positive developments in the upcoming fiscal periods.
Frequently Asked Questions
What is the date and time for STAAR's earnings call?
STAAR Surgical's earnings webcast is scheduled for February 19, 2025, at 4:30 p.m. ET / 1:30 p.m. PT.
What are the main topics to be discussed during the earnings call?
The call will cover STAAR’s financial results for Q4 2024, operational advancements, and insights into market dynamics.
How can I access the earnings call?
You can access the live earnings call through the link available on STAAR Surgical's website, where the option to pre-register will also be provided.
Will a replay of the call be available?
Yes, a replay of the call will be available approximately three hours after the live event and will remain accessible for 90 days.
What is the significance of the ICL technology?
STAAR's ICL technology offers patients visual freedom with fewer dependencies on glasses or contact lenses, making it a revolutionary option in ophthalmic surgery.
